Genoway SA
PAR:ALGEN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
FR |
Genoway SA
PAR:ALGEN
|
34.3m EUR | -10.7 | ||
US |
Abbvie Inc
NYSE:ABBV
|
297.7B USD | 8.8 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
160.2B USD | 16.5 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.2B USD | 36.5 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
114.2B USD | 29.1 | ||
AU |
CSL Ltd
ASX:CSL
|
139.1B AUD | 188 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.1B USD | 10.3 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
53.6B USD | -13.7 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -61.5 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
33.7B USD | 31.5 | ||
KR |
Celltrion Inc
KRX:068270
|
38T KRW | -458.8 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.